NeuroBo Pharmaceuticals, Inc. (NRBO) announced today promising pre-clinical data for the combination of DA-1241 and semaglutide, indicating significant improvements in liver fibrosis. The investigational drug compound also exhibited enhanced hepatoprotective effects in pre-clinical models of metabolic dysfunction-associated steatohepatitis (MASH) compared to treatments administered individually.
DA-1241 functions as a G-Protein-Coupled Receptor 119 (GPR119) agonist.
The clinical-stage biotechnology firm plans to unveil these findings through two poster presentations at the EASL Congress 2024, scheduled for June 5-8 in Milan, Italy, as well as through virtual sessions.
Hyung Heon Kim, President and CEO of NeuroBo, stated, "The data being presented at EASL reinforce the pre-clinical evidence that DA-1241's activation of GPR119 holds therapeutic promise for reducing hepatic steatosis, inflammation, and fibrosis, as well as enhancing glucose control."
Earlier in April, NeuroBo completed patient enrollment for Part 1 of its Phase 2a clinical trial of DA-1241 in MASH and is continuing to enroll patients for Part 2, which investigates the efficacy of DA-1241 in combination with sitagliptin, a DPP-4 inhibitor.
